Eckert & Ziegler reported that in the first nine months of 2011 it earned a profit of 8.8 million euros ($12 million U.S.), representing an 11% growth in profits from the same time period in 2010.
From January through September 2011, the parent company of radiotherapy and radioisotope developer Eckert & Ziegler Isotope Products had sales of 83.6 million euros ($115 million).
The Isotope Products segment accounted for the greatest sale of the total results, with an increase in revenue of 6%. The Radiopharma segment generated revenues totaling 19.1 million ($26 million).
Earnings per share for this nine-month period were 1.68 euros ($2.33), the company reported.
